Home » Stocks » VKTX

Viking Therapeutics, Inc. (VKTX)

Stock Price: $6.26 USD -0.17 (-2.64%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $6.34 +0.08 (1.28%) Dec 1, 5:59 PM

Stock Price Chart

Key Info

Market Cap 456.68M
Revenue (ttm) n/a
Net Income (ttm) -36.00M
Shares Out 72.95M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $6.26
Previous Close $6.43
Change ($) -0.17
Change (%) -2.64%
Day's Open 6.43
Day's Range 6.25 - 6.48
Day's Volume 791,729
52-Week Range 3.45 - 8.73

More Stats

Market Cap 456.68M
Enterprise Value 201.78M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 72.95M
Float n/a
EPS (basic) -0.50
EPS (diluted) -0.50
FCF / Share -0.39
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.71M
Short Ratio 9.93
Short % of Float n/a
Beta 2.13
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.92
Revenue n/a
Operating Income -40.27M
Net Income -36.00M
Free Cash Flow -28.03M
Net Cash 254.90M
Net Cash / Share 3.49
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -9.09%
ROE -13.40%
ROIC -14.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (14)

Buy 14
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(213.42% upside)
Current: $6.26
Target: 19.62
*Average 12-month price target from 13 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-32.69-26.16-19.07-13.85-12.00-23.47-0.10
Net Income-25.78-22.06-20.58-14.73-23.40-21.88-0.15
Shares Outstanding71.9657.5825.9816.286.364.192.04
Earnings Per Share-0.36-0.38-0.79-0.90-3.68-5.23-0.07
Operating Cash Flow-24.75-18.76-14.76-11.07-8.73-1.59-0.08
Free Cash Flow-24.75-18.76-14.76-11.07-8.73-1.59-0.08
Cash & Equivalents27630220.5813.1914.180.760.18
Total Debt0.36-3.453.272.151.570.28
Net Cash / Debt27530217.129.9212.03-0.81-0.10
Book Value27729813.468.048.72-22.13-0.25
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Viking Therapeutics, Inc.
Country United States
Employees 17
CEO Brian Lian

Stock Information

Ticker Symbol VKTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VKTX
IPO Date April 29, 2015


Viking Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.